Artificial intelligence is becoming an increasingly important component of pharmaceutical research, with companies using machine learning to analyze complex biological data, identify drug targets and improve clinical development decisions. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced a collaboration with AI-focused research partner Ardigen that is intended to strengthen development of the company's BiTAC(R) oncology platform through AI-enabled target discovery and validation (https://ibn.fm/yoDH5).
Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology. VERAXA Biotech has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform. The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks.
VERAXA's Boolean “AND-gated” BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design. AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because of safety concerns. The partnership reflects a broader trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity.
The agreement brings together VERAXA's antibody engineering capabilities with Ardigen's expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects for various clients. The collaboration is expected to accelerate the identification of novel dual-target combinations that could lead to more effective and safer cancer treatments.
This partnership underscores the growing importance of AI in drug discovery, particularly in oncology where the complexity of tumor biology often requires sophisticated computational approaches to identify viable therapeutic targets. By leveraging Ardigen's AI capabilities, VERAXA aims to de-risk its development pipeline and increase the probability of success for its BiTAC platform, which is designed to selectively activate T-cells only in the presence of two specific tumor antigens, potentially reducing off-target effects.
The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA. Forward-looking statements in this article are subject to risks and uncertainties as described in the company's filings with the SEC.
